Cargando…

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15–20% of patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cicenas, Jonas, Kvederaviciute, Kotryna, Meskinyte, Ingrida, Meskinyte-Kausiliene, Edita, Skeberdyte, Aiste
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447952/ https://www.ncbi.nlm.nih.gov/pubmed/28452926 http://dx.doi.org/10.3390/cancers9050042

Ejemplares similares

SGK1 in Cancer: Biomarker and Drug Target
por: Cicenas, Jonas, et al.
Publicado: (2022)

Non-Coding RNAs in Glioma
por: Rynkeviciene, Ryte, et al.
Publicado: (2018)

brca2 and tp53 Collaborate in Tumorigenesis in Zebrafish
por: Shive, Heather R., et al.
Publicado: (2014)

Surgery for BRCA, TP53 and PALB2: a literature review
por: Song, Chin-Vern, et al.
Publicado: (2018)

Starvation mediates pancreatic cancer cell sensitivity to ferroptosis via ERK1/2, JNK and changes in the cell mesenchymal state
por: Zalyte, Egle, et al.
Publicado: (2022)

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients
por: Lee, Daphne SC, et al.
Publicado: (2012)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study
por: Zhen, David B., et al.
Publicado: (2014)

Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer
por: Vodusek, Ana Lina, et al.
Publicado: (2011)

Quality Changes of Cold-Pressed Black Cumin (Nigella sativa L.), Safflower (Carthamus tinctorius L.), and Milk Thistle (Silybum marianum L.) Seed Oils during Storage
por: Tarasevičienė, Živilė, et al.
Publicado: (2023)

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk
por: Baynes, Caroline, et al.
Publicado: (2007)

Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: characterizing a Northeast Brazilian Population
por: Felix, Gabriela ES, et al.
Publicado: (2014)

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer
por: Borcoman, Edith, et al.
Publicado: (2023)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil
por: Carraro, Dirce Maria, et al.
Publicado: (2013)

Familial history and prevalence of BRCA1, BRCA2 and TP53 pathogenic variants in HBOC Brazilian patients from a public healthcare service
por: Matta, Bruna Palma, et al.
Publicado: (2022)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Post‐operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression
por: Masugi, Yohei, et al.
Publicado: (2023)

Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years
por: Petridis, Christos, et al.
Publicado: (2019)

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
por: Evans, D G R, et al.
Publicado: (2010)

Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
por: Lazzari, Grazia, et al.
Publicado: (2021)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Breast cancer in young women: prevalence of LOH at p53, BRCA1 and BRCA2
por: Johnson, SM, et al.
Publicado: (2000)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
por: Soto, José Luis, et al.
Publicado: (2005)

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2016)

Non-pulmonary cancer risk following tuberculosis: a nationwide retrospective cohort study in Lithuania
por: Everatt, Ruta, et al.
Publicado: (2017)

Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations
por: Kim, Jinyong, et al.
Publicado: (2023)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development
por: Huo, Yanying, et al.
Publicado: (2021)

Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer
por: Hyder, Zerin, et al.
Publicado: (2020)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
por: Wieser, Verena, et al.
Publicado: (2018)

Kinases and Cancer
por: Cicenas, Jonas, et al.
Publicado: (2018)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival
por: Boursi, Ben, et al.
Publicado: (2023)

Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas
por: Pessôa, Igor Andrade, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e3fso5ai32bmpmo5v6g4vooqk9